Ocular Therapeutix Inc. (OCUL)
Ocular Therapeutix Statistics
Share Statistics
Ocular Therapeutix has 159.02M shares outstanding. The number of shares has increased by 2.67% in one year.
| Shares Outstanding | 159.02M |
| Shares Change (YoY) | 2.67% |
| Shares Change (QoQ) | 1.15% |
| Owned by Institutions (%) | 80.15% |
| Shares Floating | 133.91M |
| Failed to Deliver (FTD) Shares | 1.32K |
| FTD / Avg. Volume | 0.1% |
Short Selling Information
The latest short interest is 12.67M, so 8.06% of the outstanding shares have been sold short.
| Short Interest | 12.67M |
| Short % of Shares Out | 8.06% |
| Short % of Float | 9.34% |
| Short Ratio (days to cover) | 9.68 |
Valuation Ratios
The PE ratio is -6.98 and the forward PE ratio is -7.71. Ocular Therapeutix's PEG ratio is -0.59.
| PE Ratio | -6.98 |
| Forward PE | -7.71 |
| PS Ratio | 21.21 |
| Forward PS | 1.6 |
| PB Ratio | 4.29 |
| P/FCF Ratio | -9.94 |
| PEG Ratio | -0.59 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Ocular Therapeutix.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.66, with a Debt / Equity ratio of 0.24.
| Current Ratio | 10.66 |
| Quick Ratio | 10.59 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | -0.43 |
| Debt / FCF | -0.56 |
| Interest Coverage | -12.65 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $232.57K |
| Profits Per Employee | $-706.23K |
| Employee Count | 274 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 1.85 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -13.73% in the last 52 weeks. The beta is 1.33, so Ocular Therapeutix's price volatility has been higher than the market average.
| Beta | 1.33 |
| 52-Week Price Change | -13.73% |
| 50-Day Moving Average | 7.48 |
| 200-Day Moving Average | 8.45 |
| Relative Strength Index (RSI) | 48.31 |
| Average Volume (20 Days) | 1.28M |
Income Statement
In the last 12 months, Ocular Therapeutix had revenue of 63.72M and earned -193.51M in profits. Earnings per share was -1.22.
| Revenue | 63.72M |
| Gross Profit | 58.1M |
| Operating Income | -171.78M |
| Net Income | -193.51M |
| EBITDA | -176.14M |
| EBIT | -179.93M |
| Earnings Per Share (EPS) | -1.22 |
Balance Sheet
The company has 392.1M in cash and 75.78M in debt, giving a net cash position of 316.32M.
| Cash & Cash Equivalents | 392.1M |
| Total Debt | 75.78M |
| Net Cash | 316.32M |
| Retained Earnings | -891.08M |
| Total Assets | 457.94M |
| Working Capital | 399.63M |
Cash Flow
In the last 12 months, operating cash flow was -134.68M and capital expenditures -1.29M, giving a free cash flow of -135.97M.
| Operating Cash Flow | -134.68M |
| Capital Expenditures | -1.29M |
| Free Cash Flow | -135.97M |
| FCF Per Share | -0.86 |
Margins
Gross margin is 91.17%, with operating and profit margins of -269.57% and -303.67%.
| Gross Margin | 91.17% |
| Operating Margin | -269.57% |
| Pretax Margin | -303.67% |
| Profit Margin | -303.67% |
| EBITDA Margin | -276.42% |
| EBIT Margin | -269.57% |
| FCF Margin | -213.37% |
Dividends & Yields
OCUL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for OCUL is $17, which is 133.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $17 |
| Price Target Difference | 133.2% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 1.82 |
| Piotroski F-Score | 4 |